MEDXF News and Press, Medexus Pharmaceuticals Inc From 06/14/22

TORONTO and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 23, 2022 to discuss Medexus’s results for its fourth quarter ...

Study’s primary endpoint and key secondary endpoints were met Study found event-free survival and overall survival superior after treosulfan compared to RIC busulfan, also found non-relapse mortality lower in treosulfan arm than busulfan arm Study results accepted for publi...

TORONTO and CHICAGO, May 24, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, a strategic partner of Medexus, that medac received acknowledgement of receipt from the U.S. Food and Drug Administration ( FD...

Medexus Pharmaceuticals (OTCQX:MEDXF) said its German partner medac resubmitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for Treosulfan, in combination with chemotherapy fludarabine, as a preparative regimen for patients with certain types o...

Additional data collection and analysis reconfirms confidence in New Drug Application for Treosulfan NDA resubmission date consistent with previously announced timeline FDA decision still expected within six months of resubmission TORONTO and CHICAGO, April 22, 2022 (GLOBE NEWSW...

TORONTO and CHICAGO, April 19, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) will be presenting at the Bloom Burton & Co. Healthcare Investor Conference from May 2 to 3, 2022. The conference brings together U.S.,...

TORONTO and CHICAGO, March 09, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it will be participating in the 34 th Annual Roth Conference from March 13 to 15, 2022. ...

Medexus has acquired exclusive rights to commercialize Gleolan in the United States, complementing Medexus’s existing rights to Gleolan in Canada Gleolan is an optical imaging agent currently indicated in the United States in patients with glioma as an adjunct for the visuali...

Medexus will implement a NCIB in respect of its 6% unsecured convertible debentures due 2023 NCIB will commence on February 16, 2022 and is expected to continue for up to 12 months NCIB purchases to deleverage Medexus’s balance sheet and le...

Medexus Pharmaceuticals, Inc (MEDXF) Q3 2022 Earnings Conference Call February 10, 2022, 08:00 AM ET Company Participants Ken d’Entremont – Chief Executive Officer Marcel Konrad – Chief Financial Officer Victoria Rutherford – Investor Relations Conference Call Part...